CANINE ARTHRITIS MARKET ANALYSIS

Canine Arthritis Market, by Medication Type (NSAID’s, Corticosteroids, Opioid Pain Relievers, and Others), by Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2433
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Canine Arthritis Market – Drivers

Factors such as high adoption of pets by common people, increasing expenditure by consumers on veterinary care, and increasing number of approvals for veterinary medicines are expected to drive growth of the canine arthritis market. For instance, in March 2016, USFDA approved Galliprant — an animal drug for osteoarthritis in dogs. Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist, a non-cyclooxygenase inhibiting, non-steroidal anti-inflammatory drug (NSAID) and is intended to control pain and inflammation associated with osteoarthritis in dogs. The application for Galliprant was sponsored by Aratana Therapeutics.

Furthermore, increasing initiatives by professional business services to offer support for pet care is expected to propel the market growth. For instance, in January 2019, the International Boarding & Pet Services Association (IBPSA) appointed one Chief Operating Officer along with three new advisory boards to bring an additional and invaluable experiences of pet care business to IBPSA and its members.

However, side effects associated with canine arthritis treatments are expected to hamper growth of the canine arthritis market.